[4] SUSTAIN-6 (semaglutide) : In 3,297 high-risk patients with type 2 diabetes, once-weekly semaglutide reduced major cardiovascular events by 26% and stroke by 39% over two years
Following resection, the soft tissue adjacent to the nasopalatine nerve was electrocauterized, and the surgical site was closed with a continuous vicryl suture ( Fig
Choosing Between Semaglutide and Tirzepatide for Microdosing From a pharmacology standpoint, semaglutide is a pure GLP-1 receptor agonist , while tirzepatide is a dual GIP/GLP-1 agonist that activates both GIP and GLP-1 receptors.[2,4] That dual mechanism likely contributes to tirzepatides strong weight-loss results at full doses compared with semaglutide in head-to-head and indirect comparisons.[2,7] In the context of microdosing: Some clinicians and patients feel that microdosing tirzepatide provides robust appetite control even at relatively low doses, though this is based largely on real-world experience rather than large trials
doi: 10.3945/jn.109.113332 51 KimH-JBaeS-C
Research into this blend has proposed potential roles in countering age-related degeneration, supporting collagen synthesis, and reducing oxidative damage
